HC Wainwright & Co. Maintains Buy on Kyntra Bio, Lowers Price Target to $18

Benzinga · 2d ago
HC Wainwright & Co. analyst Matthew Keller maintains Kyntra Bio (NASDAQ:KYNB) with a Buy and lowers the price target from $43 to $18.